Similar Papers

Paper Title
Journal
Date
Author
Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia
Abhishek Maiti ...
Blood | VOL. 136
Abhishek Maiti, et. al.Abhishek Maiti ...
05 Nov 2020
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response
Naval Daver ...
Blood | VOL. 136
Naval Daver, et. al.Naval Daver ...
05 Nov 2020
Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib
Kiyomi Morita ... Elias Jabbour
Blood | VOL. 136
Kiyomi Morita, et. al.Kiyomi Morita ... Elias Jabbour
05 Nov 2020
Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
Nicholas J Short ...
Blood | VOL. 136
Nicholas J Short, et. al.Nicholas J Short ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
The JAK2 46/1 haplotype influences PD-L1 expression.
Gonzalo Carreño-Tarragona ... Miguel Manzanares
Blood | VOL. -
Gonzalo Carreño-Tarragona, et. al.Gonzalo Carreño-Tarragona ... Miguel Manzanares
07 Feb 2025
Targeting cell surface VISTA expression on allospecific naïve T cells promotes tolerance.
Brent H Koehn ... Bruce R Blazar
Blood | VOL. -
Brent H Koehn, et. al.Brent H Koehn ... Bruce R Blazar
07 Feb 2025
Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
Ioannis Mantzaris ... Eric J Feldman
Blood | VOL. -
Ioannis Mantzaris, et. al.Ioannis Mantzaris ... Eric J Feldman
07 Feb 2025
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.